The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. In some cases, the composition includes sucrose acetate isobutyrate, biodegradable polymer, hydrophobic solvent, and a complex comprising a counterion and beneficial agent, such as protein, peptide, nucleic acid, or small molecular weight compound. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. In some cases, the composition includes sucrose acetate isobutyrate, biodegradable polymer, hydrophobic solvent, and a complex comprising a counterion and beneficial agent, such as protein, peptide, nucleic acid, or small molecular weight compound. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.

The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.

The present disclosure provides method of making a nanoparticle complex wherein the nanoparticle complex comprises a ligand and a metal cation. The disclosure also provides nanoparticle complexes, methods of treating a disease in a patient utilizing the nanoparticle complexes, methods of identifying a disease in a patient utilizing the nanoparticle complexes, and kits involving the nanoparticle complexes.

The present disclosure provides method of making a nanoparticle complex wherein the nanoparticle complex comprises a ligand and a metal cation. The disclosure also provides nanoparticle complexes, methods of treating a disease in a patient utilizing the nanoparticle complexes, methods of identifying a disease in a patient utilizing the nanoparticle complexes, and kits involving the nanoparticle complexes.

This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.